Physician profile
Christopher D Davis
NPI 1861026049
$326.55
in general payments reported to CMS, 2019-2025
11 companies · $51.78 in 2025
The $51.78 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.44 · 2022: $110 · 2023: $49.16 · 2024: $15.71 · 2025: $51.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $64.87 | 2023-2024 | Nuedexta, Rexulti |
| Opko Pharmaceuticals, LLC | $60.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.93 | 2021-2022 | |
| Vifor Pharma, INC. | $34.82 | 2021-2022 | |
| Amgen INC. | $27.30 | 2021-2022 | |
| Astellas Pharma US INC | $20.42 | 2025 | Veozah |
| Daiichi Sankyo INC. | $16.11 | 2022 | |
| Exact Sciences Corporation | $16.11 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $13.88 | 2022 | |
| Urovant Sciences INC | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.